Gilead Sciences, Inc. (GILD) CEO Daniel O'Day on Q1 2020 Results - Earnings Call Transcript

Apr. 30, 2020 11:20 PM ETGilead Sciences, Inc. (GILD)3 Comments
SA Transcripts profile picture
SA Transcripts

Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2020 Earnings Conference Call April 30, 2020 4:30 PM ET

Company Participants

Doug Maffei - Senior Director of Investor Relations

Daniel O'Day - Chairman and Chief Executive Officer

Andrew Dickinson - Chief Financial Officer

Johanna Mercier - Chief Commercial Officer

Merdad Parsey - Chief Medical Officer

Christi Shaw - Chief Executive Officer of Kite

Diana Brainard - SVP and Head of HIV and Emerging Viruses Therapeutic Area

Conference Call Participants

Michael Yee - Jefferies

Cory Kasimov - JP Morgan

Brian Abrahams - RBC Capital Markets

Geoff Meacham - Bank of America

Geoffrey Porges - SVB Leerink

Matthew Harrison - Morgan Stanley

Umer Raffat - Evercore

Alethia Young - Cantor Fitzgerald

Mohit Bansal - Citigroup

Robyn Karnauskas - SunTrust

Salim Syed - Mizuho

Tyler Van Buren - Piper Sandler

Phil Nadeau - Cowen and Company


Ladies and gentlemen, thank you for standing by. And welcome to the First Quarter 2020 Gilead Sciences Earnings Conference Call. At this time, all participants are in a listen-only mode [Operator Instructions]. Please be advised that today’s conference is being recorded [Operator Instructions].

It is now my pleasure to introduce Senior Director of Investor Relations, Doug Maffei.

Doug Maffei

Thank you, Andrew, and good afternoon, everyone. Just after market closed today, we issued a press release with earnings results for first quarter 2020. The press release and detailed slides are available on the Investor Relations section of the Gilead Web site.

The speakers on today's call will be Daniel O'Day, Chairman and Chief Executive Officer and Andrew Dickinson, Chief Financial Officer. Also on the will be Johanna Mercier, Chief Commercial Officer; Merdad Parsey, Chief Medical Officer; Christi Shaw, Chief Executive Officer of Kite; and Diana Brainard, SVP and Head of HIV and Emerging Viruses Therapeutic Area.

Before we begin with

Recommended For You

Comments (3)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.